Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families
Lianna Ishihara(University of Cambridge), Fayçal Hentati(National Institute of Neurology Mongi-Ben Hamida), Rajesh Pahwa(University of Kansas Medical Center), David J. Burn(Newcastle Hospitals - Campus for Ageing and Vitality), N. Gouider‐Khouja(National Institute of Neurology Mongi-Ben Hamida), Nobutaka Hattori(RIKEN Center for Brain Science), Jina Swartz(GlaxoSmithKline (United Kingdom)), Linda Surh(Children's Hospital of Eastern Ontario), Liling Warren, Lefkos Middleton(Imperial College Healthcare NHS Trust), Catherine L. Wielinski, Samia Ben Yahmed(Institut National de Santé Publique), Leigh Ragone(Research Triangle Park Foundation), Ramu Elango(GlaxoSmithKline (United Kingdom)), Kevin H. Reeves(Research Triangle Park Foundation), P. Anthony Akkari(Research Triangle Park Foundation), Siwan Thomas(GlaxoSmithKline (United Kingdom)), Rachel A. Gibson(GlaxoSmithKline (United Kingdom)), Joseph Jankovic(Baylor College of Medicine), Rim Amouri(Tunis University), Ray L. Watts, David Leppert, Christine Hunter(Baylor College of Medicine), M. Zouari(Institut National de Santé Publique), Samia Ben Sassi(Institut National de Santé Publique), Martha Nance(Hennepin County), Mounir Kefi(Institut National de Santé Publique), Kelly E. Lyons(University of Kansas Medical Center), Alan Freeman(Emory University), Ghada El Euch‐Fayeche(Institut National de Santé Publique)
Cited by 92
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
|Nature Genetics|2000|2k
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
|The Journal of Cell Biology|2010|1.9k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k